These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 38577753)

  • 21. [Sublingual use of atropine for clozapine-induced sialorrhoea: literature review and two case reports].
    van der Poorten T; De Hert M
    Tijdschr Psychiatr; 2019; 61(6):403-410. PubMed ID: 31243750
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Botulinum toxin A: a new option for treatment of drooling in children with cerebral palsy. Presentation of a case series.
    Jongerius PH; Rotteveel JJ; van den Hoogen F; Joosten F; van Hulst K; Gabreëls FJ
    Eur J Pediatr; 2001 Aug; 160(8):509-12. PubMed ID: 11548191
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A review of options for treating sialorrhea in amyotrophic lateral sclerosis.
    Banfi P; Ticozzi N; Lax A; Guidugli GA; Nicolini A; Silani V
    Respir Care; 2015 Mar; 60(3):446-54. PubMed ID: 25228780
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Intraparotid injection of botulinum toxin A as a treatment to control sialorrhea in children with cerebral palsy.
    Savarese R; Diamond M; Elovic E; Millis SR
    Am J Phys Med Rehabil; 2004 Apr; 83(4):304-11; quiz 312-4, 336. PubMed ID: 15024333
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effectiveness of the pharmacological treatments for sialorrhea in patients with Parkinson's disease: a systematic review and network meta-analysis.
    Santos Junior LC; Santos JR; Reis A; Faria-E-Silva AL; Leal PC
    Clin Oral Investig; 2023 Jun; 27(6):2449-2463. PubMed ID: 37036514
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Treatment of sialorrhea with botulinum toxin: an overview].
    Hagenah J; Kahl KG; Steinlechner S; Lencer R; Klein C
    Nervenarzt; 2005 Apr; 76(4):418-25. PubMed ID: 15448912
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A critical review of incobotulinumtoxinA in the treatment of chronic sialorrhea in pediatric patients.
    Jost WH; Steffen A; Berweck S
    Expert Rev Neurother; 2021 Oct; 21(10):1059-1068. PubMed ID: 34516331
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Sialorrhea: a review of a vexing, often unrecognized sign of oropharyngeal and esophageal disease.
    Boyce HW; Bakheet MR
    J Clin Gastroenterol; 2005 Feb; 39(2):89-97. PubMed ID: 15681902
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacological interventions for treating sialorrhea associated with neurological disorders: A mixed treatment network meta-analysis of randomized controlled trials.
    Sridharan K; Sivaramakrishnan G
    J Clin Neurosci; 2018 May; 51():12-17. PubMed ID: 29475576
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Potential problems surrounding the use of sublingually administered ophthalmic atropine for sialorrhea.
    Leung JG; Schak KM
    Schizophr Res; 2017 Jul; 185():202-203. PubMed ID: 28043733
    [No Abstract]   [Full Text] [Related]  

  • 31. Long-lasting benefits of botulinum toxin type B in Parkinson's disease-related drooling.
    Lagalla G; Millevolte M; Capecci M; Provinciali L; Ceravolo MG
    J Neurol; 2009 Apr; 256(4):563-7. PubMed ID: 19401804
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Botulinum toxin-A injections vs radiotherapy for drooling in ALS.
    Weikamp JG; Schinagl DA; Verstappen CC; Schelhaas HJ; de Swart BJ; Kalf JG
    Acta Neurol Scand; 2016 Sep; 134(3):224-31. PubMed ID: 26803950
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Salivary gland ablation: introducing an interventional radiology treatment alternative in the management of sialorrhea.
    Begley KA; Braswell LE; Noritz GH; Murakami JW
    Pediatr Radiol; 2020 May; 50(6):869-876. PubMed ID: 32198665
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Up-to-date report of botulinum toxin therapy in patients with drooling caused by different etiologies.
    Ellies M; Laskawi R; Rohrbach-Volland S; Arglebe C
    J Oral Maxillofac Surg; 2003 Apr; 61(4):454-7. PubMed ID: 12684962
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Nonsurgical treatment of drooling in a patient with closed head injury and severe dysarthria.
    Dworkin JP; Nadal JC
    Dysphagia; 1991; 6(1):40-9. PubMed ID: 1884637
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Reduction of salivary flow with botulinum toxin: extended report on 33 patients with drooling, salivary fistulas, and sialadenitis.
    Ellies M; Gottstein U; Rohrbach-Volland S; Arglebe C; Laskawi R
    Laryngoscope; 2004 Oct; 114(10):1856-60. PubMed ID: 15454785
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Factors in the Efficacy, Safety, and Impact on Quality of Life for Treatment of Drooling with Botulinum Toxin Type A in Patients with Cerebral Palsy.
    Gonzalez-L MD; Martinez C; Bori Y Fortuny I; Suso-Vergara S
    Am J Phys Med Rehabil; 2017 Feb; 96(2):68-76. PubMed ID: 28099276
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Surgical management of chronic sialorrhea in pediatric patients: 10-year experience from one tertiary care institution.
    Formeister EJ; Dahl JP; Rose AS
    Int J Pediatr Otorhinolaryngol; 2014 Aug; 78(8):1387-92. PubMed ID: 24974144
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Treatment of severe drooling with botulinum toxin in amyotrophic lateral sclerosis and Parkinson's disease: efficacy and possible mechanisms.
    Møller E; Karlsborg M; Bardow A; Lykkeaa J; Nissen FH; Bakke M
    Acta Odontol Scand; 2011 May; 69(3):151-7. PubMed ID: 21198339
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmacokinetics and Effects on Saliva Flow of Sublingual and Oral Atropine in Clozapine-Treated and Healthy Adults: An Interventional Cross-Over Study.
    Mubaslat O; Fitzpatrick M; McLachlan AJ; Lambert T
    Psychiatry Clin Psychopharmacol; 2022 Mar; 32(1):17-27. PubMed ID: 38764898
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.